Igor Horrillo

Igor Horrillo

Auto-generated profile, based on publicly available information

Igor Horrillo

Department of Pharmacology, University of the Basque Country EHU, Leioa, Bizkaia, Spain

Research Focus & Metrics

Academic Career Length

16Years (2011-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2013 in Biological Psychiatry
Verified
Journal Article
Closed access
CACristina Alba-Delgado
Cristina Alba-Delgado
MLMeritxell Llorca-Torralba
Meritxell Llorca-Torralba
IHIgor Horrillo
Igor Horrillo
JOJorge E. Ortega
Jorge E. Ortega
JMJuan Antonio Mico
Juan Antonio Mico
EBEsther Berrocoso
Esther Berrocoso

1 April 2012 in Neuropharmacology
Verified
Journal Article
Closed access
EMEva Martisova
Eva Martisova
MSMaite Solas
Maite Solas
IHIgor Horrillo
Igor Horrillo
JOJorge E. Ortega
Jorge E. Ortega
JMJ Javier Meana
J Javier Meana
Maria Javier RamirezMaria Javier Ramirez
Maria Javier Ramirez

1 July 2020 in European Neuropsychopharmacology
Verified
Journal Article
Open access
IMItziar Muneta-Arrate
Itziar Muneta-Arrate
RDRebeca Diez-Alarcia
Rebeca Diez-Alarcia
IHIgor Horrillo
Igor Horrillo
JMJ Javier Meana
J Javier Meana
Pimavanserin is claimed as the first antipsychotic drug that shows selectivity for serotonin 5-HT2 receptors (5-HT2Rs) and lacks of affinity for dopamine D2 receptors (D2Rs). Cell-based functional assays suggest that pimavanserin and antipsychotics with D2R/5-HT2R affinity could act as inverse agonists of 5-HT2ARs. However, there is not evidence of such pharmacological profile in native brain tissue. 5-HT2ARs are able to engage both canonical Gαq/11- and non-canonical Gαi1-proteins. In the present study, the response to pimavanserin of the 5-HT2AR coupling to Gαq/11- and Gαi1-proteins was measured in membranes of postmortem human prefrontal cortex by antibody-capture [35S]GTPγS binding scintillation proximity assays. Pimavanserin promoted a concentration-dependant inhibition of the 5-HT2AR coupling to Gαi1-proteins whereas the response of Gαq/11-proteins was unaltered, suggesting inverse agonism and neutral antagonism properties, respectively. The inhibition was abolished in the presence of the selective 5-HT2AR antagonist MDL-11,939 and was absent in brain cortex of 5-HT2AR knock-out mice when compared to respective 5-HT2AR wild-type animals. In conclusion, the results demonstrate the existence of constitutive 5-HT2AR activity in human brain for the signalling pathway mediated by Gαi1-proteins. Pimavanserin demonstrates 5-HT2AR functional selectivity and exhibits inverse agonist profile towards Gαi1-proteins, which is considered the effector pathway promoting hallucinogenic responses. In contrast, pimavanserin behaves as neutral antagonist on the 5-HT2AR coupling to the canonical Gαq/11-protein pathway. The results strengthen the relevance of inverse agonism as potential mechanism of antipsychotic activity. Moreover, the existence of functional selectivity of 5-HT2ARs for different Gα-proteins could contribute to better design of 5-HT2AR-related antipsychotic drugs.

29 October 2011 in Psychopharmacology
Verified
Journal Article
Closed access
PDF file
CACristina Alba-Delgado
Cristina Alba-Delgado
GBGisela Borges
Gisela Borges
PSPilar Sánchez-Blázquez
Pilar Sánchez-Blázquez
JOJorge E. Ortega
Jorge E. Ortega
IHIgor Horrillo
Igor Horrillo
EBEsther Berrocoso
Esther Berrocoso

1 June 2013 in European Journal of Pharmacology
Verified
Journal Article
Closed access
JOJorge Emilio Ortega
Jorge Emilio Ortega
VGVictor Gonzalez-Lira
Victor Gonzalez-Lira
IHIgor Horrillo
Igor Horrillo
MHMario Herrera-Marschitz
Mario Herrera-Marschitz
LCLuis Callado
Luis Callado
JMJ Javier Meana
J Javier Meana

14 June 2025 in Translational Psychiatry
Verified
Journal Article
Open access
PDF file
IEInes Erkizia-Santamaría
Ines Erkizia-Santamaría
IHIgor Horrillo
Igor Horrillo
NMNerea Martínez-Álvarez
Nerea Martínez-Álvarez
DPDaniel Pérez-Martínez
Daniel Pérez-Martínez
GRGuadalupe Rivero
Guadalupe Rivero
JOJorge E. Ortega
Jorge E. Ortega
Depression and anxiety are disabling and high incidence mental disorders characterized by phenotypic heterogeneity. Currently available treatments show severe limitations. Thus, there is an urgent need for effective treatments in this population. In the search for novel rapid-acting antidepressants, the psychedelic psilocybin has emerged as a promising therapy in several clinical trials. However, its antidepressant mechanism of action is still not well understood. The aim of the present study was to evaluate the therapeutic potential of psilocybin in ameliorating the adverse behavioural and neurochemical consequences of chronic stress. To this end, a chronic unpredictable mild stress (CUMS) animal model was used, and psilocybin treatment was administered (two doses of 1 mg/kg, i.p., administered 7 days apart). Psilocybin reversed impairments in anhedonia and behavioural despair dimensions of depressive phenotype but not in apathy-related behaviour. Psilocybin administration was also able to exert an anxiolytic-like effect on treated animals. Physiological alterations caused by stress, indicative of a hyperactive hypothalamic-pituitary-adrenal axis (HPA), were not reversed by psilocybin. When neuroplasticity-related proteins were assessed in cerebral cortex, brain-derived neurotrophic factor (BDNF) was found to be decreased in stressed animals, and treatment did not reverse such impairment. Psilocybin administration increased the expression and function of serotonin-2A-receptor (5HT2AR) in brain cortex of control and CUMS groups. Furthermore, psilocybin treatment caused a selective increase in the expression of glucocorticoid-receptor (GR) in brain cortex of CUMS mice. In conclusion, psilocybin was able to rescue impairments in the depressive phenotype, and to induce anxiolytic-like effects. Furthermore, an enhancement in sensitivity to psilocybin-induced HTR was observed following a booster dose. Altogether, this work provides new knowledge on the putative benefit/risk actions of psilocybin and contributes to the understanding of the therapeutic mechanism of action of psychedelics.